1. Introduction {#sec1}
===============

Ischemia-reperfusion (I/R) is a well-recognized pathological condition that is characterized by an initial deprivation of blood supply to an area or organ followed by subsequent vascular restoration and concomitant reoxygenation of downstream tissue \[[@B1]\]. I/R can develop as a consequence of trauma, hypertension, shock, sepsis, organ transplantation, or bypass surgery leading to end-organ failure such as acute renal tubular necrosis, bowel infarct, and liver failure. I/R can also occur under various complications of vascular diseases such as stroke and myocardial infarction \[[@B1], [@B2]\]. Several pathophysiologic mechanisms have been proposed as mediators of the damage induced by I/R, such as activation of the complement system and leukocyte recruitment, endoplasmic reticulum stress, calcium overload, reduction of oxidative phosphorylation, increased free radical concentration, development of the no-reflow phenomenon, endothelial dysfunction, and activation of signaling pathways of apoptosis, necrosis, and/or autophagy \[[@B1], [@B3]\]. Many studies have shown that there are three time frames in the protection against I/R injury: before the index ischemic episode (ischemic preconditioning), during ischemia (ischemic conditioning), and at the onset of reperfusion (ischemic postconditioning) \[[@B4], [@B5]\]. Currently, several therapeutic gases have been shown to play a role in the treatment of I/R injury, including hydrogen, nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H~2~S) \[[@B6]\].

H~2~S is a colorless, flammable, and water-soluble gas with the characteristic smell of rotten eggs. In the past several centuries, H~2~S had been known only for its toxicity and environmental hazards \[[@B7], [@B8]\]. It elicits its toxic effects by reversibly inhibiting cytochrome c oxidase (CcO), preventing oxidative phosphorylation and lowering the production of adenosine triphosphate (ATP). Recently, there has been growing evidence that H~2~S plays a broad range of physiological and pathophysiological functions \[[@B9], [@B10]\], including induction of angiogenesis \[[@B11]\], regulation of neuronal activity \[[@B9]\], vascular relaxation \[[@B12]\], glucose homeostatic regulation \[[@B13]\], and protection against I/R injury in heart, liver, kidney, lung, and brain \[[@B14]--[@B18]\]. The abnormal metabolism of H~2~S could result in an array of pathological disturbances in the form of hypertension, diabetes, atherosclerosis, heart failure, sepsis, inflammation, erectile dysfunction, cataracts, asthma, and neurodegenerative diseases \[[@B10]\]. In addition, H~2~S can also interact with other specific molecules, including NO \[[@B19]\], CcO \[[@B20]\], catalase \[[@B21]\], myoglobin \[[@B21], [@B22]\], hemoglobin \[[@B21], [@B22]\], Kelch-like ECH-associated protein 1 (Keap1) \[[@B23]\], cysteine residues on ATP-sensitive potassium (K~ATP~) channels \[[@B24]\], epidermal growth factor receptor \[[@B25]\], and vascular endothelial growth factor receptor 2 \[[@B25], [@B26]\]. Considering H~2~S is involved in numerous biological processes, it is now widely accepted that H~2~S functions as the third signaling gasotransmitter, along with NO and CO \[[@B9]\].

With the deepening of research on H~2~S and I/R injury, the role that H~2~S plays in attenuating I/R injury has begun to be elucidated. In this review, we highlight recent studies that provide new insight into the production and metabolism of H~2~S and discuss the role and mechanism of H~2~S on I/R injury.

2. Production and Metabolism of **H~2~**S {#sec2}
=========================================

2.1. Endogenous Production of H~2~S {#sec2.1}
-----------------------------------

H~2~S is endogenously generated in mammalian cells via both enzymatic and nonenzymatic pathways, although the nonenzymatic pathway is less important in H~2~S production \[[@B27]\]. With regard to the enzymatic pathway, cystathionine *β*-synthase (CBS) and cystathionine *γ*-lyase (CSE) are two pyridoxal-5′-phosphate- (PLP-) dependent enzymes, which use either L-cysteine or L-cysteine together with homocysteine as their principal substrates to produce H~2~S \[[@B9]\]. Unlike CBS and CSE, 3-mercaptopyruvate sulfurtransferase (3-MST) is a PLP-independent enzyme, which uses 3-mercaptopyruvate (3MP) as a substrate to produce H~2~S. 3MP is a metabolite of L-cysteine and *α*-ketoglutarate by cysteine aminotransferase (CAT) \[[@B9]\]. CSE and CBS are cytosolic enzymes with tissue-specific distributions. CBS is predominantly expressed in the central nervous system and is also found in liver, kidney, ileum, uterus, placenta, and pancreatic islets. CSE is abundant in heart, liver, kidney, uterus, ileum, placenta, and vascular smooth muscle. CSE is the most relevant H~2~S-producing enzyme in the cardiovascular system \[[@B9], [@B27]\]. CAT and 3-MST are localized both in cytosol and mitochondria, but the majority of these two enzymes are present in the mitochondria \[[@B9]\]. They have been found in the heart, kidney, liver, lung, thymus, testis, brain, and thoracic aorta and are apparently important for H~2~S production in the brain and vasculature \[[@B9], [@B27], [@B28]\]. Furthermore, a recent study has demonstrated that D-cysteine (a negative control of L-cysteine) can be metabolized to achiral 3MP by D-amino acid oxidase and can be used as a substrate for 3-MST to produce H~2~S in both kidney and brain \[[@B29]\]. During the enzymatic pathway, H~2~S can be immediately released or stored in a form of bound or acid-labile sulfur in the cells \[[@B30]\].

Apart from enzymatic pathway, endogenous H~2~S can also be produced through nonenzymatic processes that are less well understood \[[@B27], [@B30], [@B31]\]. Nonenzymatic production of H~2~S occurs through glucose, inorganic, and organic polysulfides (present in garlic), glutathione, and elemental sulfur \[[@B30], [@B31]\]. H~2~S can be generated from glucose either via glycolysis (\>90%) or from phosphogluconate via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (\<10%) \[[@B7], [@B27], [@B30]\]. Glucose could react with cysteine, methionine, or homocysteine to produce gaseous sulfur compounds such as H~2~S and methanethiol \[[@B7], [@B8], [@B30]\]. H~2~S is also produced through direct reduction of glutathione and elemental sulfur. Reduction of elemental sulfur to H~2~S is mediated through reducing equivalents of the glucose oxidation pathways such as nicotinamide adenine dinucleotide and NADPH \[[@B7], [@B8]\]. Thiosulfate is an intermediate of sulfur metabolism from cysteine and H~2~S formation from thiosulfate through a reductive reaction involving pyruvate, which acts as a hydrogen donor \[[@B7], [@B8], [@B32], [@B33]\]. In addition, garlic and garlic-derived organic polysulfides could induce H~2~S production in a thiol-dependent manner, such as diallyl sulfide (DAS), diallyl disulfide (DADS), diallyl trisulfide (DATS), and S-allyl cysteine (SAC) \[[@B30]--[@B34]\].

2.2. Exogenous Source of H~2~S {#sec2.2}
------------------------------

H~2~S gas has been considered as the authentic resource of exogenous H~2~S \[[@B35]\]. Recent studies have shown that H~2~S gas plays important roles in promoting angiogenesis \[[@B11]\], ameliorating type II diabetes \[[@B13]\], and protecting against myocardial I/R injury \[[@B36]\]. However, H~2~S gas is not an ideal resource due to a possible toxic impact of H~2~S excess and difficulty in obtaining precisely controlled concentration \[[@B35]\]. Currently, a number of H~2~S-releasing compounds have already been successfully designed and developed. These compounds could be mainly divided into two types, including the "H~2~S donors," which release H~2~S as the only mechanism of action, and the "H~2~S-releasing hybrid drugs," also known as "dirty drugs" in which H~2~S release is an ancillary property which accompanies a principal mechanism of the hybrid drugs \[[@B35]\]. Inorganic sulfide salts, such as sodium hydrosulfide (NaHS), sodium sulfide (Na~2~S), and calcium sulfide, have been widely used as H~2~S donors \[[@B7], [@B8], [@B35]\]. As the maximum concentration of H~2~S released from these salts can be reached within seconds, they have been called fast-releasing H~2~S donors \[[@B35]\]. However, the effective residence time of these donors in tissues may be very short because H~2~S is highly volatile in solutions \[[@B35]\]. Ideal H~2~S donors for therapeutic purposes should generate H~2~S with relatively slow-releasing rates and longer periods of treating time. Recently, many slow-releasing H~2~S donors ([Table 1](#tab1){ref-type="table"}) and H~2~S-releasing hybrid drugs ([Table 2](#tab2){ref-type="table"}) have been designed and synthesized to increase the treatment efficacy of H~2~S.

2.3. Metabolism of H~2~S {#sec2.3}
------------------------

In order to maintain a proper physiological balance of its metabolism, H~2~S can be broken down through several enzymatic and nonenzymatic processes \[[@B7], [@B10], [@B37]\]. The main pathway of H~2~S catabolism occurs in mitochondria. Mitochondrial oxidative modification converts H~2~S into thiosulfate through several enzymes including quinone oxidoreductase, S-dioxygenase, and S-transferase. Thiosulfate could be further converted into sulfite, which is catalyzed by thiosulfate : cyanide sulfurtransferase. Sulfite is then rapidly oxidized to sulfate by sulfite oxidase. Therefore, sulfate is a major end-product of H~2~S metabolism under physiological conditions \[[@B7], [@B10], [@B37], [@B38]\]. The secondary mechanism of H~2~S catabolism is the methylation to methanethiol and dimethylsulfide via thiol S-methyltransferase in the cytosol \[[@B10], [@B37], [@B38]\]. The third pathway of H~2~S metabolism is the interaction of H~2~S with methemoglobin that leads to sulfhemoglobin, which is considered as a possible biomarker of plasma H~2~S \[[@B10], [@B37], [@B38]\]. These three pathways are considered the main processes of H~2~S catabolism in mammals. Furthermore, recent studies have shown that H~2~S could be converted into sulfite via minor oxidative routes in activated neutrophils \[[@B10], [@B37]\].

3. **H~2~**S and I/R Injury {#sec3}
===========================

3.1. H~2~S and Myocardial I/R Injury {#sec3.1}
------------------------------------

Myocardial ischemia is a common clinical symptom characterized by low pH values, low oxygen, and high extracellular potassium concentration, which may cause arrhythmias, cardiac dysfunction, myocardial infarction, and sudden death \[[@B3], [@B5], [@B6]\]. The damaged myocardial structure and decreased heart function induced by ischemia can be repaired with subsequent reperfusion. The effectiveness of reperfusion depends on the duration and severity of prior ischemia \[[@B6], [@B39]\]. However, myocardial reperfusion could also activate a complex inflammatory response, which may finally lead to myocardial ischemia/reperfusion injury (MIRI), such as arrhythmias, myocardial stunning, microvascular dysfunction, and myocyte death \[[@B2], [@B40]\]. Therefore, it is necessary to develop effective cardioprotective strategies and agents against MIRI to improve myocardial function and to reduce the risk of cardiovascular events \[[@B4]\]. H~2~S is now considered as an endogenous signaling molecule which plays an important role in the cardiovascular system \[[@B6], [@B15], [@B27]\]. In the heart, H~2~S is produced in the fibroblasts, myocardium, and blood vessels from L-cysteine by CSE, CBS, and 3-MST and accumulates at relatively high local concentrations \[[@B6], [@B27], [@B30]\]. An accumulating body of evidence indicates that exogenous or endogenous H~2~S could exert cardioprotection against MIRI in cardiac myocytes, isolated hearts, and intact animals. However, it is currently difficult to define the precise underlying mechanisms for this protection. A summary of what is known about the mechanisms by which H~2~S and its donors-induced cardioprotection against MIRI is shown in [Table 3](#tab3){ref-type="table"}.

3.2. H~2~S and Hepatic I/R Injury {#sec3.2}
---------------------------------

Liver I/R-induced injury represents a continuum of organic processes that could produce profound liver damage and ultimately lead to morbidity and mortality \[[@B41], [@B42]\]. Hepatic I/R injury has now been considered a worldwide health problem and usually occurs in liver transplantation, hemorrhagic shock and resuscitation, trauma, liver resection surgery, and aortic injury during abdominal surgery \[[@B41]--[@B43]\]. Hepatic I/R injury can be categorized into warm I/R and cold storage reperfusion injury, which share a common mechanism in the disease aetiology \[[@B41], [@B42]\]. Increasing number of experimental and clinical studies indicate that pathways/factors involved in the hepatic I/R injury include liver Kupffer cells and neutrophils, intracellular calcium overload, oxidative stress, anaerobic metabolism, mitochondria, adhesion molecules, chemokines, and proinflammatory cytokines \[[@B41], [@B42], [@B44], [@B45]\]. Despite significant advances in surgical techniques and perioperative cares, hepatic I/R injury remains one of the major complications in hepatic resection and transplantation \[[@B46]\]. Novel agents/drugs exhibiting antioxidative, anti-inflammatory, and cytoprotective activities may be possible candidates for protecting the liver from I/R injury \[[@B46]\]. Recent studies have shown that H~2~S could significantly attenuate hepatic I/R injury in several ways, including inflammation, apoptosis, oxidation, and AKT activation ([Table 4](#tab4){ref-type="table"}). The results suggest that H~2~S has a protective effect against hepatic I/R injury, and targeting H~2~S may present a promising approach against I/R-induced liver injury.

3.3. H~2~S and Renal I/R Injury {#sec3.3}
-------------------------------

Acute kidney injury (AKI) is a common and serious complication of critical illness and is associated with high morbidity, mortality, and resource utilization \[[@B25], [@B47], [@B48]\]. Renal I/R injury is one of the leading causes of AKI in many clinical settings \[[@B47], [@B48]\]. Renal I/R injury often arises from shock and various surgical procedures such as kidney transplantation and resection \[[@B47]--[@B49]\]. H~2~S plays important physiological and pathological roles in the kidney \[[@B48]\]. For instance, it participates in the control of renal function and increases urinary sodium excretion via both tubular and vascular actions in the kidney \[[@B50]\]. CSE deficiency in mice could lead to reduced renal H~2~S production and increase severity of damage and mortality after renal I/R injury, which indicates that H~2~S may play a role in alleviating renal I/R injury \[[@B14]\]. More recently, there is growing evidence regarding the beneficial effects of H~2~S on ameliorating renal I/R injury mainly via a variety of antioxidant, antiapoptotic, and anti-inflammatory effects ([Table 5](#tab5){ref-type="table"}). These studies indicate that H~2~S and its donors may be of benefit in conditions associated with renal I/R injury, such as renal transplantation.

3.4. H~2~S and Cerebral I/R Injury {#sec3.4}
----------------------------------

Ischemic cerebrovascular disease is one of the most common disorders that greatly threaten human health with high morbidity, disability, and mortality \[[@B51]\]. Cerebral I/R injury is mainly characterized by a deterioration of ischemic but potentially salvageable brain tissue of an ischemic injury after reperfusion \[[@B52], [@B53]\]. There are a number of risk factors involved in cerebral I/R injury, such as excitotoxicity, mitochondrial dysfunction, formation of free radicals, breakdown of the blood-brain barrier (BBB), edema, neuroinflammation, and apoptosis \[[@B52]--[@B54]\]. Emerging evidences indicate that H~2~S functions not only as a neuromodulator, but also as a neuroprotectant in the central nervous system \[[@B18], [@B55]--[@B57]\]. In an*in vivo* model of cerebral I/R injury, treatment with low concentration of H~2~S decreased the infarct size and improved the neurological function via antiapoptotic effect, implying that H~2~S has a therapeutic role in cerebral ischemic stroke \[[@B18], [@B57]\]. DAS, an H~2~S donor, could also protect the brain from I/R injury partly via its antiapoptotic effects \[[@B58]\]. ADT, another H~2~S donor, decreased the infarct size and protected BBB integrity by suppressing local inflammation and nicotinamide adenine dinucleotide phosphate oxidase 4-derived ROS generation \[[@B55]\]. However, it is notable that the effects of H~2~S on cerebral I/R injury are controversial \[[@B56]\]. Treatment with a higher dose of exogenous H~2~S donor could deteriorate the effects of cerebral I/R injury \[[@B18], [@B59]\]. These opposite effects of H~2~S on cerebral I/R injury may be partially associated with the concentration of H~2~S in brain. This research offers a novel insight for future studies on the cytoprotective effects of a proper dose of H~2~S on central nervous system degenerative diseases, such as Alzheimer\'s disease and Parkinson\'s disease.

3.5. H~2~S and Intestinal I/R Injury {#sec3.5}
------------------------------------

Intestinal I/R injury is considered to be a major and frequent problem in many clinical conditions, including intestinal mechanical obstruction, abdominal aortic aneurysm surgery, cardiopulmonary bypass, strangulated hernias, liver and intestinal transplantation, mesenteric artery occlusion, shock, and severe trauma \[[@B60]--[@B64]\]. This injury can lead to the development of systemic inflammatory response syndrome and multiple organ dysfunction syndrome \[[@B62], [@B63]\]. Although many advanced treatments have been applied to clinical research, the mortality induced by intestinal I/R injury remains very high \[[@B61], [@B63]\]. Therefore, it is urgent to develop new therapeutic agents/drugs for the treatment of intestinal I/R injury. Recent studies have shown that H~2~S has anti-ischemic activity in the intestinal I/R model. NaHS could significantly reduce the severity of intestinal I/R injury and dramatically increase the activities of SOD and glutathione peroxidase (GSH-Px) in both serum and intestinal tissue, which suggests that H~2~S protects against intestinal I/R injury by increasing the levels of antioxidant enzymes \[[@B63]\]. In addition, administration of NaHS after the onset of ischemia can attenuate I/R-induced damage of intestinal tissues both*in vitro* and*in vivo* \[[@B65]\]. These observations provide new insight regarding the potential use of H~2~S as a therapeutic agent to limit intestinal I/R injury.

3.6. H~2~S and Gastric I/R Injury {#sec3.6}
---------------------------------

Gastric I/R injury is an important and common clinical problem which could lead to mucosal injury \[[@B66]\]. A number of clinical conditions contribute to gastric I/R injury, including peptic ulcer bleeding, vascular rupture or surgery, ischemia gastrointestinal disease, and hemorrhagic shock \[[@B66]\]. However, there are few satisfactory clinical methods in the treatment of gastric I/R injury \[[@B67]\]. H~2~S has been found to play an important role in protecting against gastric I/R injury. Endogenous H~2~S had a protective effect against gastric I/R in rats by enhancing the antioxidant capacity through increasing the contents of GSH and SOD \[[@B68]\]. Another study has shown that NaHS and L-cysteine could protect the gastric mucosa against I/R damage mainly mediated by altering mRNA expression and plasma release of proinflammatory cytokines \[[@B69]\]. Furthermore, NaHS and L-cysteine also showed gastroprotective effects against I/R injury by Keap1 s-sulfhydration, nuclear factor-kappa B dependent anti-inflammation, and mitogen-activated protein kinase dependent antiapoptosis pathway \[[@B66]\]. Thus, H~2~S and its donors may have potential therapeutic value in acute gastric mucosal lesion, which is often caused by I/R.

3.7. H~2~S and Hind-Limb I/R Injury {#sec3.7}
-----------------------------------

I/R injury can occur in skeletal muscle during elective surgery (i.e., free tissue transfer) and lower extremity arterial occlusion \[[@B70], [@B71]\]. Limb I/R injury may result in a series of postreperfusion syndromes, such as crush syndrome, compartment syndrome, and myonephropathic-metabolic syndrome \[[@B72]\]. Currently, clinical practice mainly focuses on reducing the duration of ischemia to minimize the ischemic injury in skeletal muscle \[[@B70], [@B71]\]. Therapeutic interventions that change the biochemical environment during the ischemic and/or reperfusion period may result in amelioration of subsequent cellular damage \[[@B71]\]. Treatment with NaHS for 20 minutes before the onset of hind-limb ischemia or reperfusion could result in significant protection against the cellular damage induced by I/R \[[@B71], [@B73]\]. However, administration of NaHS for 1 minute before reperfusion did not show any protection against limb I/R Injury \[[@B73]\]. Whether H~2~S could protect against limb I/R injury in a dose- and time-dependent manner needs further investigation.

3.8. H~2~S and Lung I/R Injury {#sec3.8}
------------------------------

Lung I/R injury occurs in various clinical conditions such as lung transplantation, cardiopulmonary bypass, trauma, cardiac bypass surgery, sleeve lobectomy, shock, pulmonary embolism, resuscitation from circulatory arrest, and reexpansion pulmonary edema \[[@B16], [@B74]--[@B77]\]. Lung I/R injury is characterized by increased pulmonary vascular resistance, worsened lung compliance, poor lung oxygenation, edema, and increased pulmonary endothelial permeability \[[@B16], [@B78]\]. Currently, there is no effective therapy available for the lung I/R injury. The precise mechanism of lung I/R injury needs to be further elucidated \[[@B16], [@B74]\]. A recent study has shown that preperfusion with H~2~S could attenuate the lung I/R injury by reducing lung oxidative stress \[[@B16]\], which suggests that administration of H~2~S or its donors might be a novel preventive and therapeutic strategy for lung I/R injury.

3.9. H~2~S and Retinal I/R Injury {#sec3.9}
---------------------------------

Retinal I/R injury is a common clinical condition and is associated with the loss of neurons, morphological degeneration of the retina, loss of retinal function, and ultimately vision loss \[[@B79], [@B80]\]. Emerging evidence suggests that retinal I/R injury plays an important role in the pathologic processes of several ocular diseases such as diabetic retinopathy, retinopathy of prematurity, acute glaucoma, and retinal vascular occlusion \[[@B81], [@B82]\]. Retinal I/R injury often results in visual impairment and blindness because of the lack of effective treatment \[[@B81], [@B83]\]. One recent study has indicated that rapid preconditioning with inhaled H~2~S can mediate antiapoptotic effects and thus protect the rat retina against I/R injury \[[@B84]\]. ACS67, a H~2~S-releasing derivative of latanoprost acid, possesses neuroprotective properties and could attenuate retinal ischemia*in vivo* and decrease the oxidative insult to RGC-5 cells (retinal ganglion cells)*in vitro* \[[@B85]\]. These results suggest that H~2~S represents a novel and promising therapeutic agent to counteract neuronal injuries in the eye \[[@B84]\]. Further studies are needed to prove the neuroprotective propensity of H~2~S in retinal I/R injury using a postconditioning approach.

4. Concluding Remarks {#sec4}
=====================

H~2~S is now considered as the third signaling gasotransmitter which plays a broad range of physiological and pathophysiological functions, including vascular relaxation, induction of angiogenesis, regulation of neuronal activity, and glucose homeostatic regulation. H~2~S can be endogenously generated via both enzymatic and nonenzymatic pathways and mainly metabolized through three pathways in mammals. However, whether H~2~S could be generated and metabolized via another pathway should be further studied and confirmed. In addition, more efforts should be made to illuminate the expressions and functions of H~2~S-generating enzymes in different organ and tissue. In order to increase the treatment efficacy of H~2~S, a number of slow-releasing H~2~S donors and H~2~S-releasing hybrid drugs have been successfully designed, synthesized, and proved to be effective*in vitro*,*ex vivo*, and*in vivo*. Novel synthetic strategy should be developed to extend the exposure time of H~2~S donor. Agents/drugs with antiapoptotic, antioxidative, anti-inflammatory, and antitumor effects could be conjugated with H~2~S donor to enhance their therapeutic effects. Furthermore, new drug targeting carrier systems should be designed to effectively transport the H~2~S donor to the targeted organ or tissue.

I/R is a pathological condition that is characterized by an initial deprivation of blood supply to an area or organ followed by the subsequent restoration of perfusion and concomitant reoxygenation. Novel mechanisms associated with I/R need to be further studied and illuminated in addition to the existing pathophysiologic mechanisms. Increasing number of studies have shown that H~2~S could protect against I/R injury in many organs and tissues, such as heart, liver, kidney, brain, intestine, stomach, hind-limb, lung, and retina. Whether H~2~S could exert protection against I/R injury in other organs and/or tissues need to be further demonstrated. In addition, the molecular targets of H~2~S in I/R injury are also needed to be clarified. Ischemic preconditioning, conditioning, and postconditioning are three time frames in the protection against I/R injury. Proper time frame and optimal duration of treatment should be confirmed according to the physicochemical property of H~2~S-releasing compounds. Considering different doses of H~2~S-releasing compounds may exert different therapeutic effects, proper dose range should also be further explored to obtain a better therapeutic efficacy. Currently, researches into the molecular mechanisms of H~2~S in I/R injury using animal experiments have made some progress. Clinical evidence-based research should also be useful in further exploring the little-understood field of the role of H~2~S in I/R injury. In addition, longer-term studies are required to determine whether H~2~S treatment permanently improves organ function following I/R injury and whether this effect reduces long-term morbidity and mortality.

In conclusion, with the rapid developments of design and synthetic strategies, as well as better understanding of the precise mechanisms behind the role of H~2~S in I/R injury, treatment with H~2~S or its donors in proper dose range and time frame will exhibit more potent therapeutic effects against I/R injury in further preclinical research and clinical application.
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###### 

The biological characteristics of slow-releasing H~2~S donors.

  Compounds                                                               H~2~S release mechanisms               Therapeutic effects                                     References
  ----------------------------------------------------------------------- -------------------------------------- ------------------------------------------------------- -------------
  GYY4137                                                                 Hydrolysis                             Vasodilation                                            \[[@B86]\]
  Anti-inflammation                                                       \[[@B19]\]                                                                                     
  Anticancer                                                              \[[@B87]\]                                                                                     
  Protection of mitochondrial function                                    \[[@B88]\]                                                                                     
  Regulation of oviductal embryo transport and myometrial contractility   \[[@B89], [@B90]\]                                                                             
  Antithrombotic                                                          \[[@B91]\]                                                                                     
                                                                                                                                                                         
  ADT                                                                     Metabolized by carboxylesterases       Neuroprotection against oxidative stress                \[[@B92]\]
  Protection of blood-brain barrier integrity                             \[[@B55]\]                                                                                     
                                                                                                                                                                         
  ADT-OH                                                                  Metabolized by carboxylesterases       Neuroprotection against oxidative stress                \[[@B92]\]
  Vasorelaxation                                                          \[[@B93]\]                                                                                     
  Antineuroinflammation                                                   \[[@B94]\]                                                                                     
                                                                                                                                                                         
  AP39                                                                    Metabolized by carboxylesterases       Protection against oxidative mitochondrial DNA damage   \[[@B95]\]
                                                                                                                                                                         
  S-Aroylthiooximes                                                       Hydrolysis                             Unknown                                                 \[[@B96]\]
                                                                                                                                                                         
  S-Propargyl-cysteine                                                    Hydrolysis                             Angiogenesis promotion                                  \[[@B97]\]
  Anticancer                                                              \[[@B98]\]                                                                                     
  Cardioprotection                                                        \[[@B99]\]                                                                                     
  Anti-inflammation                                                       \[[@B100]\]                                                                                    
                                                                                                                                                                         
  SG-1002                                                                 Activation after oral administration   Cardioprotection                                        \[[@B101]\]
                                                                                                                                                                         
  4-Hydroxythiobenzamide                                                  Hydrolysis                             Improvement of wound healing                            \[[@B102]\]
                                                                                                                                                                         
  Arylthioamides                                                          Thiol activation                       Unknown                                                 \[[@B103]\]
                                                                                                                                                                         
  N-(benzoylthio)benzamides                                               Hydrolysis                             Unknown                                                 \[[@B104]\]
                                                                                                                                                                         
  S-Propyl cysteine                                                       Hydrolysis                             Cardioprotection                                        \[[@B99]\]
                                                                                                                                                                         
  *N*-Acetylcysteine                                                      Hydrolysis                             Protection against oxidative stress                     \[[@B105]\]
                                                                                                                                                                         
  *N*-Acetylcysteine ethyl ester                                          Hydrolysis                             Protection against oxidative stress                     \[[@B105]\]
                                                                                                                                                                         
  SAC^\*^                                                                 Hydrolysis                             Protection against oxidative stress                     \[[@B99]\]
                                                                                                                                                                         
  PhNCS                                                                   Thiol activation                       Unknown                                                 \[[@B106]\]
                                                                                                                                                                         
  PhNCS-COOH                                                              Thiol activation                       Unknown                                                 \[[@B106]\]
                                                                                                                                                                         
  Lawesson\'s reagent                                                     Hydrolysis                             Anti-inflammation                                       \[[@B107]\]
  Protection against gastric damage                                       \[[@B108]\]                                                                                    
                                                                                                                                                                         
  Dithioperoxyanhydrides                                                  Thiol activation                       Vasorelaxation                                          \[[@B35]\]
                                                                                                                                                                         
  Thioglycine                                                             Bicarbonate activation                 Unknown                                                 \[[@B109]\]
                                                                                                                                                                         
  L-Thiovaline                                                            Bicarbonate activation                 Unknown                                                 \[[@B109]\]
                                                                                                                                                                         
  Thioamino acids                                                         Bicarbonate activation                 Vasorelaxation                                          \[[@B109]\]
                                                                                                                                                                         
  Phosphorodithioates                                                     Hydrolysis                             Protection against oxidative stress                     \[[@B35]\]
                                                                                                                                                                         
  S-SH compounds                                                          Thiol activation                       Myocardial I/R protection                               \[[@B110]\]
                                                                                                                                                                         
  N-(acylthio)-benzamides                                                 Thiol activation                       Unknown                                                 \[[@B104]\]
                                                                                                                                                                         
  H~2~S photo-donor **5**                                                 Light activation                       Unknown                                                 \[[@B111]\]
                                                                                                                                                                         
  *gem*-Dithiol compounds                                                 Light activation                       Unknown                                                 \[[@B35]\]
                                                                                                                                                                         
  Allyl isothiocyanate                                                    Thiol activation                       Unknown                                                 \[[@B112]\]
                                                                                                                                                                         
  Benzyl isothiocyanate                                                   Thiol activation                       Unknown                                                 \[[@B112]\]
                                                                                                                                                                         
  4-Hydroxybenzyl isothiocyanate                                          Thiol activation                       Unknown                                                 \[[@B112]\]
                                                                                                                                                                         
  Erucin                                                                  Thiol activation                       Unknown                                                 \[[@B112]\]
                                                                                                                                                                         
  Sinigrin                                                                Hydrolysis                             Unknown                                                 \[[@B112]\]
                                                                                                                                                                         
  Poly(ethylene glycol)-ADT                                               Metabolized by carboxylesterases       Unknown                                                 \[[@B113]\]
                                                                                                                                                                         
  S-memantine                                                             Thiol activation                       Protection against ischemic neuronal death              \[[@B114]\]
                                                                                                                                                                         
  ACS1                                                                    Metabolized by carboxylesterases       Neuroprotection                                         \[[@B115]\]
  Anticancer                                                              \[[@B116]\]                                                                                    

^\*^This compound is also a derivative of garlic.

###### 

The biological characteristics of H~2~S-releasing hybrid drugs.

  Compounds                                    Parent drugs                    Therapeutic effects                           References
  -------------------------------------------- ------------------------------- --------------------------------------------- -------------
  ACS2                                         Valproic acid                   Anticancer                                    \[[@B116]\]
  Antiangiogenesis                             \[[@B117]\]                                                                   
                                                                                                                             
  ACS6                                         Sildenafil                      Proerectile                                   \[[@B118]\]
  Neuroprotection                              \[[@B119]\]                                                                   
  Protection against oxidative stress          \[[@B120]\]                                                                   
                                                                                                                             
  ACS14                                        Aspirin                         Protection against oxidative stress           \[[@B121]\]
  Prevent the progression of atherosclerosis   \[[@B122]\]                                                                   
  Antiaggregatory                              \[[@B123]\]                                                                   
  Protection against I/R injury                \[[@B124]\]                                                                   
  Modulation of thiol homeostasis              \[[@B125]\]                                                                   
  Neuroprotection                              \[[@B115]\]                                                                   
                                                                                                                             
  ACS15^\*^                                    Diclofenac                      Anticancer                                    \[[@B126]\]
  Antiosteolysis                               \[[@B127]\]                                                                   
  Anti-inflammation                            \[[@B128]\]                                                                   
  Antiangiogenesis                             \[[@B117]\]                                                                   
                                                                                                                             
  ACS18                                        Sulindac                        Anticancer                                    \[[@B126]\]
  Antiangiogenesis                             \[[@B117]\]                                                                   
                                                                                                                             
  ACS21                                        Salicylic acid                  Protection against I/R injury                 \[[@B124]\]
                                                                                                                             
  ACS32                                        Diclofenac                      Antiosteolysis                                \[[@B127]\]
                                                                                                                             
  ACS33                                        Valproic acid                   Anticancer                                    \[[@B129]\]
  Inhibition of histone deacetylase activity   \[[@B129]\]                                                                   
                                                                                                                             
  ACS67                                        Latanoprost                     Regulation of insulin secretion               \[[@B114]\]
  Neuroprotection                              \[[@B85]\]                                                                    
                                                                                                                             
  ACS83                                        L-DOPA                          Anti-inflammation                             \[[@B130]\]
                                                                                                                             
  ACS84                                        L-DOPA                          Anti-inflammation                             \[[@B131]\]
  Neuroprotection                              \[[@B132]\]                                                                   
                                                                                                                             
  ACS85                                        L-DOPA                          Anti-inflammation                             \[[@B118]\]
                                                                                                                             
  ACS86                                        L-DOPA                          Anti-inflammation                             \[[@B118]\]
                                                                                                                             
  ATB-284                                      Unknown                         Prevention against irritable bowel syndrome   \[[@B133]\]
                                                                                                                             
  ATB-337^\*^                                  Diclofenac                      Anti-inflammation                             \[[@B134]\]
                                                                                                                             
  ATB-343                                      Indomethacin                    Anti-inflammation                             \[[@B135]\]
                                                                                                                             
  ATB-345                                      Naproxen                        Anti-inflammation                             \[[@B136]\]
                                                                                                                             
  ATB-346                                      Naproxen                        Anti-inflammation                             \[[@B136]\]
  Anticancer                                   \[[@B137]\]                                                                   
                                                                                                                             
  ATB-429                                      Mesalamine                      Anti-inflammation                             \[[@B138]\]
  Abirritation                                 \[[@B139]\]                                                                   
                                                                                                                             
  HS-aspirin (HS-ASA)                          Aspirin                         Anticancer                                    \[[@B140]\]
                                                                                                                             
  Compound **8e**                              3-n-Butylphthalide              Antithrombosis                                \[[@B141]\]
                                                                                                                             
  H2S-EXP 3174                                 Active metabolite of losartan   Vasorelaxation                                \[[@B142]\]
                                                                                                                             
  NOSH-aspirin (NBS-1120)                      Aspirin                         Anticancer                                    \[[@B143]\]
  Anti-inflammation                            \[[@B144]\]                                                                   
                                                                                                                             
  NOSH-naproxen (AVT-219)                      Naproxen                        Anti-inflammation                             \[[@B145]\]
                                                                                                                             
  NOSH-sulindac (AVT-18A)                      Sulindac                        Anti-inflammation                             \[[@B145]\]
                                                                                                                             
  S-diclofenac^\*^                             Diclofenac                      Anti-inflammation                             \[[@B146]\]
  Protection against I/R injury                \[[@B146]\]                                                                   
                                                                                                                             
  S-zofenopril                                 Zofenopril                      Improvement of vascular function              \[[@B147]\]

^\*^These compounds are remarkably similar to each other.

###### 

Effects of H~2~S and its donors in myocardial I/R injury.

  Experimental models                              Effects                                                                                                                            Proposed mechanisms                                                                                          References
  ------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ -------------
  Myocardial I/R *in vivo*(rat)                    NaHS (0.2 mg/kg, prior to R) protects against the effects of haemorrhage-induced I/R                                               Upregulation of the protein kinase B/endothelial nitric oxide synthase pathway                               \[[@B148]\]
                                                                                                                                                                                                                                                                                                   
  Regional myocardial I/R*in vivo*(rat)            NaHS (3 mg/kg, 15 min prior to I) shows cardioprotective effects                                                                   Combination of antiapoptotic and anti-inflammatory effects                                                   \[[@B149]\]
                                                                                                                                                                                                                                                                                                   
  Isolated perfused heart *ex vivo* (rat)          NaHS (100 *μ*M, plus histidine buffer solution, prior to R) enhances cardiac performance                                           Prevention of apoptosis and preservation of the phosphorylative system                                       \[[@B150]\]
                                                                                                                                                                                                                                                                                                   
  Isolated perfused heart *ex vivo* (rat)          NaHS (0.1--100 *μ*M, at the onset of R) protects rat heart against I/R injury                                                      Mitochondrial K~ATP~ channel opening                                                                         \[[@B151]\]
                                                                                                                                                                                                                                                                                                   
  Primary cultured neonatal cardiomyocytes (rat)   NaHS (25--200 *μ*M, 30 min prior to H) protects cardiomyocytes from oxidative stress                                               Inhibition of mitochondrial complex IV and enhancement of SOD activity                                       \[[@B152]\]
                                                                                                                                                                                                                                                                                                   
  Isolated perfused heart *ex vivo* (rat)          NaHS (10 *μ*M, at the onset of R) protects isolated rat hearts from I/R injury                                                     Activation of the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway        \[[@B153]\]
                                                                                                                                                                                                                                                                                                   
  Isolated perfused heart *ex vivo* (rat)          NaHS (40 *μ*M, throughout the experiment) provides myocardial protection                                                           Possibly activation of the expression of heat shock protein 72                                               \[[@B154]\]
                                                                                                                                                                                                                                                                                                   
  Isolated perfused heart *ex vivo* (rat)          L-cysteine (0.1--10 mM, 10 min before I until 10 min after R) induces limitation of infarct size                                   Dependent on H~2~S synthesis                                                                                 \[[@B155]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(rat)                    NaHS (14 *μ*M/kg, 7 days before myocardial I/R) significantly reduces the myocardial infarct size                                  Antiapoptotic, antioxidative, and anti-inflammatory activities                                               \[[@B156]\]
                                                                                                                                                                                                                                                                                                   
  Isolated perfused heart *ex vivo* (rat)          NaHS (100 *μ*M, prior to I) significantly decreases the duration and severity of I/R-induced arrhythmias                           Mitochondrial K~ATP~ channel opening                                                                         \[[@B157]\]
                                                                                                                                                                                                                                                                                                   
  Isolated perfused heart *ex vivo* (rat)          NaHS (100 *μ*M, prior to I) significantly decreases myocardial infarct size and improves heart contractile function                Activation of K~ATP~/PKC/ERK1/2 and PI3K/Akt pathways                                                        \[[@B158]\]
                                                                                                                                                                                                                                                                                                   
  Isolated cardiac myocytes (rat)                  NaHS (100 *μ*M, prior to I) increases cell viability, percentage of rod-shaped cells, and myocyte contractility                    K~ATP~/PKC dependent induction of COX-2 expression and nitric oxide-induced COX-2 activation                 \[[@B159]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(mice)                   H~2~S (100 ppm, prior to I) has protective properties in I/R injury                                                                Reduction of myocardial ROS production and the inhibition of inflammation, necrosis, and fibrogenesis        \[[@B36]\]
                                                                                                                                                                                                                                                                                                   
  Regional myocardial I/R*in vivo*(pig)            Na~2~S (100 *μ*g/kg bolus + 1 mg/kg/hr infusion, 10 min prior to R) improves myocardial function and reduces infarct size          Anti-inflammatory properties                                                                                 \[[@B160]\]
                                                                                                                                                                                                                                                                                                   
  Regional myocardial I/R*in vivo*(pig)            Na~2~S (100 *μ*g/kg bolus + 1 mg/kg/hr infusion, throughout the experiment) reduces myocardial infarct size                        Antiapoptotic activities                                                                                     \[[@B161]\]
                                                                                                                                                                                                                                                                                                   
  Regional myocardial I/R*in vivo*(rat)            NaHS (0.1--10 *μ*M, 10 min prior to I until 10 min into R) results in a concentration-dependent limitation of infarct size         Mitochondrial K~ATP~ channel opening                                                                         \[[@B162]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(rat)                    NaHS (0.2 mg/kg, prior to R) protects against the effects of haemorrhage-induced I/R                                               Protection against oxidative stress                                                                          \[[@B163]\]
                                                                                                                                                                                                                                                                                                   
  Primary cultured neonatal cardiomyocytes (rat)   NaHS (1--100 *μ*M, 30 min prior to H) shows concentration-dependent inhibitory effects on cardiomyocyte apoptosis induced by H/R   Induction of phosphorylation of GSK-3 and inhibition of mitochondrial permeability transition pore opening   \[[@B164]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(mice)                   Na~2~S (0.1 mg/kg, 7 days prior to I) attenuates myocardial I/R injury                                                             Activation of nuclear factor erythroid-2-related factor-2 signaling in an Erk-dependent manner               \[[@B165]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(rat)                    NaHS (14 *μ*M/kg, 7 days prior to I) inhibits apoptosis of cardiomyocytes induced by myocardial I/R                                Enhancement of the phosphorylation of apoptosis repressor with caspase recruitment domain                    \[[@B166]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(mice)                   Na~2~S (10--500 *μ*g/kg, prior to R) limits infarct size and preserves left ventricular function                                   Inhibition of myocardial inflammation and preservation of both mitochondrial structure and function          \[[@B167]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(mice)                   Na~2~S (100 *μ*g/kg, 1 h prior to I) reduces myocardial infarct size                                                               miR-21-dependent attenuation of ischemic and inflammatory injury                                             \[[@B168]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(mice)                   Na~2~S (100 *μ*g/kg, 24 h prior to I) reduces myocardial infarct size                                                              Combination of antioxidant and antiapoptotic signaling                                                       \[[@B169]\]
                                                                                                                                                                                                                                                                                                   
  Isolated perfused heart *ex vivo* (rabbit)       Allitridum (60 *μ*M, prior to I) reduces myocardial infarct size                                                                   Activation of PKC                                                                                            \[[@B170]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(mice)                   DATS (200 *μ*g/kg, prior to R) significantly reduces infarct size and increases myocardial contractile function                    Preservation of endogenous hydrogen sulfide and increase of nitric oxide bioavailability                     \[[@B32]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(mice)                   Na~2~S (100 *μ*g/kg, prior to R) protects against the structural and functional deterioration of the left ventricle                Protection against oxidative stress and mitochondrial dysfunction                                            \[[@B15]\]
                                                                                                                                                                                                                                                                                                   
  Isolated perfused heart *ex vivo* (rat)          NaHS (50 *μ*M, prior or post to I) protects against cardiac I/R injury                                                             Phosphorylation of mammalian target of rapamycin C2                                                          \[[@B171]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(rat)                    NaHS (3 mg/kg, 15 min prior to I) significantly reduces myocardial infarct size                                                    Mitochondrial K~ATP~ channel opening                                                                         \[[@B172]\]
                                                                                                                                                                                                                                                                                                   
  Primary cultured neonatal cardiomyocytes (rat)   NaHS (30 *μ*M, 30 min prior to H) attenuates cardiomyocyte apoptosis and enhances cell viability                                   Protection of cardiomyocytes against I/R-induced apoptosis by stimulating Bcl-2                              \[[@B173]\]
                                                                                                                                                                                                                                                                                                   
  Isolated perfused heart *ex vivo* (mice)         Na~2~S (10 *μ*M, 40 seconds after the start of R) markedly improves the recovery of myocardial function                            Nitric oxide synthase 3-dependent signaling pathway                                                          \[[@B174]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(rat)                    NaHS (14 *μ*M/kg/d, 6 d prior to I) markedly reduces heart infarct size and has great improvement in blood pressure                Upregulation of survivin                                                                                     \[[@B175]\]
                                                                                                                                                                                                                                                                                                   
  Myocardial I/R *in vivo*(pig)                    NaHS (0.2 mg/kg, prior to R) markedly reduces myocardial infarct size and improves regional left ventricular function              Higher expression of phospho-GSK-3*β* and lower expression of apoptosis-inducing factor                      \[[@B176]\]

H/R: hypoxia/reoxygenation; SOD: superoxide dismutase; PKC: protein kinase C; ERK1/2: extracellular signal regulated kinase 1/2; PI3K (PtdIns3K): phosphatidylinositol 3-kinase; Akt (PKB): protein kinase B; COX-2: cyclooxygenase-2; ROS: reactive oxygen species; GSK-3: glycogen synthase kinase-3.

###### 

Effects of H~2~S and its donors in hepatic I/R injury.

  Experimental models           Effects                                                                                                                                        Proposed mechanisms                                                                                                                       References
  ----------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- -------------
  Hepatic I/R *in vivo*(rat)    NaHS (28 *μ*M/kg, prior to R) attenuates the injured hepatic function and the synthetic action of hepatocytes                                  Inhibition of lipid peroxidation and inflammation reactions                                                                               \[[@B177]\]
                                                                                                                                                                                                                                                                                                                         
  Hepatic I/R *in vivo*(mice)   NaHS (1.5 mg/kg, 1 h prior to I) protects against hepatic I/R injuries                                                                         Activation of the PtdIns3K-AKT1 pathway                                                                                                   \[[@B17]\]
                                                                                                                                                                                                                                                                                                                         
  Hepatic I/R *in vivo*(rat)    NaHS (14 *μ*M/kg, 30 min prior to I) significantly attenuates the severity of liver injury and inhibits the production of lipid peroxidation   Antioxidant and antiapoptotic activities                                                                                                  \[[@B46]\]
                                                                                                                                                                                                                                                                                                                         
  Hepatic I/R *in vivo*(rat)    DAS (1.75 mM/kg, 12--15 h prior to I) protects the liver from warm I/R injury                                                                  Induction of heme oxygenase-1 and inhibition of cytochrome P450 2E1                                                                       \[[@B178]\]
                                                                                                                                                                                                                                                                                                                         
  Hepatic I/R *in vivo*(mice)   Na~2~S (1 mg/kg, 5 min prior to R) protects the murine liver against I/R injury                                                                Upregulation of intracellular antioxidant and antiapoptotic signaling pathways                                                            \[[@B179]\]
                                                                                                                                                                                                                                                                                                                         
  Hepatic I/R *in vivo*(mice)   H~2~S (100 ppm, 5 min prior to R) protects the liver against I/R injury                                                                        Reduction of necrosis, apoptosis, and inflammation                                                                                        \[[@B180]\]
                                                                                                                                                                                                                                                                                                                         
  Hepatic I/R *in vivo*(mice)   NaHS (14 and 28 *μ*M/kg, 30 min prior to I) attenuates hepatic I/R injury                                                                      Weaken the apoptosis through the inhibition of c-Jun N-terminal protein kinase 1 signaling pathway                                        \[[@B181]\]
                                                                                                                                                                                                                                                                                                                         
  Hepatic I/R *in vivo*(rat)    NaHS (12.5, 25 and −50 *μ*M/kg, 5 min prior to I) reduces liver damage after perioperative I/R injury                                          Inhibition of mitochondrial permeability transition pore opening, reduction of cell apoptosis, and activation of Akt-GSK-3*β* signaling   \[[@B182]\]

###### 

Effects of H~2~S and its donors in renal I/R injury.

  Experimental models                        Effects                                                                                                                                  Proposed mechanisms                                          References
  ------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ -------------
  Renal I/R *in vivo*(mice)                  NaHS (1 mg/kg, 15 min prior to I) rescues mice from the injury and mortality                                                             Modulation of oxidative stress                               \[[@B14]\]
                                                                                                                                                                                                                                                   
  Renal I/R *in vivo*(mice)                  H~2~S (100 ppm, before and after treatment) shows protective effects on survival, renal function, apoptosis, and inflammation            A hypometabolic state induced by H~2~S                       \[[@B183]\]
                                                                                                                                                                                                                                                   
  Renal I/R *in vivo*(pig)                   Na~2~S (100 *µ*g/kg, 10 min prior to R) results in a marked reduction in kidney injury and preserves glomerular function                 Anti-inflammatory effects                                    \[[@B184]\]
                                                                                                                                                                                                                                                   
  Isolated perfused kidney *ex vivo* (pig)   H~2~S (0.5 mM, 10 min before and after R) ameliorates the renal dysfunction                                                              Activation of K~ATP~ channels                                \[[@B185]\]
                                                                                                                                                                                                                                                   
  Renal I/R *in vivo*(mice)                  NaHS (100 *µ*M/kg, 30 min prior to I) significantly attenuates I/R injury-induced renal dysfunction                                      The increase in expression of CSE                            \[[@B186]\]
                                                                                                                                                                                                                                                   
  Renal I/R *in vivo*(rat)                   NaHS (100 *µ*M/kg, 15 min prior to I and 5 min prior to R) attenuates renal I/R injury                                                   Antiapoptotic and anti-inflammatory effects                  \[[@B187]\]
                                                                                                                                                                                                                                                   
  Warm renal I/R *in vivo*(rat)              NaHS (150 *µ*M, at time of renal pedicle clamping and during R) improves long-term renal function and decreases long-term inflammation   Antiapoptotic and anti-inflammatory effects                  \[[@B188]\]
                                                                                                                                                                                                                                                   
  Warm renal I/R *in vivo*(rat)              NaHS (150 *µ*M, during I and R) increases renal capillary perfusion and improves acute tubular necrosis and apoptosis                    Decrease of leukocyte migration and inflammatory responses   \[[@B189]\]
                                                                                                                                                                                                                                                   
  Renal I/R *in vivo*(pig)                   Na~2~S (2 mg/kg, 2 h prior to I) attenuates tissue injury and organ dysfunction                                                          Antioxidant and anti-inflammatory effects                    \[[@B190]\]
                                                                                                                                                                                                                                                   
  Renal I/R *in vivo*(rat)                   NaHS (100 *µ*g/kg, 20 min prior to I or 10 min prior to R) protects against renal I/R injury                                             Antioxidant and antiapoptotic effects                        \[[@B191]\]
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